Onconetix Sets Second 1-for-10 Reverse Split, Effective November 6
ONCO is trading near its 52-week low of $0.38 (7.9% above the low) on light trading volume (0.2× avg).
Summary
Onconetix will execute another 1-for-10 reverse split effective November 6, 2026, cutting outstanding shares from about 5.9 million to roughly 589,000 and completing the 1-for-100 aggregate ratio approved by shareholders.
Key Events · Corporate Governance and Compliance · ONCO
-
Second 1-for-10 Split Declared
The board acted on October 22, 2026 to effect a 1-for-10 reverse split; combined with the May 21, 2026 split, this produces the full 1-for-100 aggregate ratio authorized at the April 30, 2026 special meeting.
-
Share Count Falls to ~589,000
Outstanding shares drop from approximately 5,886,774 as of October 21, 2026 to approximately 588,677, with cash paid in lieu of fractional shares.
-
Authorized Shares Stay at 250 Million
The split does not reduce the 250,000,000 authorized shares or change the $0.00001 par value, leaving authorized capital vastly larger than the post-split outstanding count.
-
Effective Date and New CUSIP
A Certificate of Amendment is expected to be filed November 5, 2026; the split takes effect at 12:01 a.m. ET on November 6, 2026, with trading split-adjusted under ONCO and a new CUSIP of 68237Q500.
Analysis · ONCO · Life Sciences
Onconetix is stacking a second 1-for-10 reverse split on top of the May 21, 2026 one, taking the aggregate to 1-for-100 — the full amount shareholders authorized in April. Outstanding shares drop from roughly 5.9 million to about 589,000, while authorized shares stay at 250 million; the split itself creates no dilution, but it leaves an enormous share-issuance runway relative to the post-split count. For a company that previously disclosed a going concern warning and is mid-way through acquiring Realbotix, a second split this soon points to persistent pressure to keep the Nasdaq listing and to clear the way for the share issuance up for a November 10 vote.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCO was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.38 to $200.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.